Raymond James Downgrades Alnylam to Outperform, Cuts Target to $315
The firm lowered its price target to $315 from $420 and kept a positive stance on the stock.
Key points
- Raymond James cut its rating to outperform from strong buy and its target to $315 from $420
- Last close before the action: $174.00 on Oct. 29, down 24.7% over 20 sessions
- Of 20 firms covering the stock, 16 rated it positive and four neutral before Friday
- Median target before the action was $350.5; the new $315 target sits below it
Raymond James downgraded Alnylam Pharmaceuticals (Nasdaq: ALNY) to outperform from strong buy before the open on Friday, Oct. 30, and cut its price target to $315 from $420.
The firm's stance remains positive. The stock closed at $174.00 on Thursday, Oct. 29, the last completed session before the action, and had fallen 24.7% over the 20 sessions to that close.
Where the rest of coverage stands
Of the 20 firms that rated Alnylam in the past year, 16 rated it positive and four rated it neutral before Friday. None rated it negative. The median price target across those firms was $350.5, with a range from $243 to $489.
The new $315 target sits below that median.
Company scale
Alnylam reported revenue of $3.71 billion for 2025, up 65% from the prior year, and net income of $313.7 million. For the quarter ended Sept. 30, revenue was $1.46 billion, up 17% from a year earlier. Cash and investments together totaled $3.59 billion as of that date.
The company filed a 10-Q on Thursday, one day before the action, and an 8-K that day.
Sources
Written with AI from analyst rating changes, SEC filings and market data, and checked against those sources before publishing. Our editorial standards.
More on Alnylam Pharmaceuticals
ALNY page →Filings, figures and price history are on the Alnylam Pharmaceuticals page.